| Objective To study the expression of Somatostatin receptor subtype 2 (SSTR2), deleted in pancreatic carcinoma locus 4 (DPC4/Smad4) in pancreatic cancerous tissue and pancreas tissue. Explore the role of SSTR2, DPC4/Smad4 and clinical mainifestations in human pancreatic carcinoma. Methods Forty-five cases of resected specimens containing carcinoma tissue and ten cases of normal pancreatic tissue were collected. Examined the expression of SSTR2, DPC4/Smad4 by SABC immunohistochemical method. The relationship between SSTR2 and DPC4/Smad4 was evaluated by Kendall's rank correlation. Results 1. Postive rates of SSTR2, DPC4/Smad4 in carcinomatous tissues delated by SABC were 31.1% and 46.7% respectively, whereas they were 80% and 90% in the matched normal tissue respectively. The expression of SSTR2, DPC4/Smad4 gene was markedly lower in pancreatic cancer tissues than in normal tissues. 2. The expression of SSTR2 was correleted with the pathologic type, SSTR2 is higher expression in well-differentiated (71.4%) cancer tissue than in middling-differentiated (27.3), and poorly-differentiated cancer tissue (X12=4.398, p <0.05; X22 =5.951, p <0.05), wherease there was no difference in DPC4/Smad4 gene. 3. There was postive corelation expression between SSTR2 and DPC4/Smad4 ( r = 0.9473, t = 4.1822, p < 0.05 ). Conclusion In most pancreatic cancer SSTR2, DPC4/Smad4 were decrease or loss expression, SSTR2 gene expression was significantly negatively correlated with the differentiation of cancer tissue. Re-expression SSTR2 and DPC4/Smad4 gene, the expression of which is lost in human panceratic adenocarcinoma can induce appoptosis and inhibit tumor angiogensis. There was postive correlation expression between SSTR2 and DPC4/Smad4. |
